News

Recently approved Alzheimer's drugs work by tagging amyloid plaques for clearance by the brain's microglia. Washington University School of Medicine in St. Louis researchers are developing an alternative approach, using a homemade antibody to directly mobilize microglia.

For the first time in fifty years, results from a phase 3 randomized, placebo-controlled trial have shown an overall survival benefit from an adjuvant therapy in patients with kidney cancer.

Salk scientists observe cannabinol's neuroprotective properties in fruit flies and identify cannabinol analogs that could serve as promising future therapeutics for traumatic brain injury, Alzheimer's, and Parkinson's.

Antipsychotic use in people with dementia is associated with elevated risks of a wide range of serious adverse outcomes including stroke, blood clots, heart attack, heart failure, fracture, pneumonia, and acute kidney injury, compared with non-use.

Researchers have discovered toxic protein particles, shaped like umbrellas, that soil bacteria known as Streptomyces secrete to squelch competitors, especially others of their own species.

University of Cambridge researchers have harnessed the power of artificial intelligence (AI) to speed up the screening of new drugs to treat Parkinson’s disease.

Alzheimer’s disease (AD) currently afflicts nearly seven million people in the U.S. Scientists at Sanford Burnham Prebys have now identified promising real-world links between common HIV drugs and a reduced incidence of AD.

Researchers have linked a region in the brain to how humans redirect thoughts and attention when distracted, offering insights into side effects of Parkinson's disease treatment.

3D-printed films loaded with drugs could be used to kill cancer cells while minimizing the toxicity of traditional chemotherapy.

Contrary to past warnings, a new study has found that a commonly prescribed dementia drug doesn't increase the risk of death or heart rhythm problems.